| 19.23 0.74 (4%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.98 | 1-year : | 26.84 |
| Resists | First : | 19.67 | Second : | 22.98 |
| Pivot price | 17.77 |
|||
| Supports | First : | 14.99 |
Second : | 12.1 |
| MAs | MA(5) : | 18.88 |
MA(20) : | 16.79 |
| MA(100) : | 12.07 |
MA(250) : | 10.13 |
|
| MACD | MACD : | 1.6  |
Signal : | 1.5 |
| %K %D | K(14,3) : | 85.5 |
D(3) : | 85.3 |
| RSI | RSI(14): 71.4 |
|||
| 52-week | High : | 19.67 | Low : | 6.06 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PHAT ] has closed below upper band by 15.9%. Bollinger Bands are 51.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 19.55 - 19.65 | 19.65 - 19.73 |
| Low: | 18.09 - 18.2 | 18.2 - 18.29 |
| Close: | 19.07 - 19.24 | 19.24 - 19.38 |
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Fri, 13 Sep 2024
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 1.6% - MarketBeat
Fri, 13 Sep 2024
Phathom Pharmaceuticals' (PHAT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Fri, 06 Sep 2024
PHAT stock touches 52-week high at $17.12 amid robust growth - Investing.com
Tue, 03 Sep 2024
Following Up On Phathom Pharmaceuticals (NASDAQ:PHAT) - Seeking Alpha
Thu, 29 Aug 2024
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Thu, 29 Aug 2024
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 4.84e+007 (%) |
| Held by Institutions | 8.8 (%) |
| Shares Short | 13,730 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.5207e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 55.4 % |
| Return on Equity (ttm) | -54.1 % |
| Qtrly Rev. Growth | 9.92e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -5.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -215 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.43 |
| Dividend | 0 |
| Forward Dividend | 1.534e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|